KALV insider transaction filings
KalVista Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-11. Screen KALV transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | Arif Bilal — Chief Operations Officer | Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 49,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Treanor Patrick — Director | Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Sensenig Bethany — Director | Disposition to issuer (D): 45,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Disposition to issuer (D): 150,260 @ $0 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 25,800 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 68,750 (derivative) · Disposition to issuer (D): 93,750 (derivative) | EDGAR |
| 2026-06-11 | 4 | Sweeny Nicole — Chief Commercial Officer | Disposition to issuer (D): 59,291 @ $0 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 68,750 (derivative) · Disposition to issuer (D): 93,750 (derivative) | EDGAR |
| 2026-06-11 | 4 | Piekos Brian — Chief Financial Officer | Disposition to issuer (D): 21,661 @ $0 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 55,000 (derivative) · Disposition to issuer (D): 93,750 (derivative) | EDGAR |
| 2026-06-11 | 4 | Fairey William — Director | Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Disposition to issuer (D): 229,918 @ $0 · Disposition to issuer (D): 53,500 (derivative) · Disposition to issuer (D): 52,600 (derivative) · Disposition to issuer (D): 27,900 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 31,000 (derivative) · +5 more | EDGAR |
| 2026-06-11 | 4 | Stuart Nancy — Director | Disposition to issuer (D): 14,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Reid Laurence — Director | Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2026-06-11 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Disposition to issuer (D): 479,989 @ $0 · Disposition to issuer (D): 47,354 (derivative) · Disposition to issuer (D): 29,611 (derivative) · Disposition to issuer (D): 33,800 (derivative) · Disposition to issuer (D): 71,700 (derivative) · Disposition to issuer (D): 52,600 (derivative) · +12 more | EDGAR |
| 2026-06-11 | 4 | Unkart Edward W — Director | Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) · +4 more | EDGAR |
| 2026-06-11 | 4 | Pereira Brian JG — Director | Disposition to issuer (D): 14,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +1 more | EDGAR |
| 2026-05-29 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Option exercise (M): 33,800 @ $7.07 · Sale (S): 33,800 @ $26.78 · Option exercise (M): 33,800 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 · Sale (S): 2,239 @ $26.78 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Sweeny Nicole — Chief Commercial Officer | Option exercise (M): 5,000 · Sale (S): 1,489 @ $26.78 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Option exercise (M): 3,125 · Sale (S): 1,966 @ $26.78 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 6,250 · Sale (S): 2,685 @ $26.78 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Sweeny Nicole — Chief Commercial Officer | Option exercise (M): 6,250 · Sale (S): 1,861 @ $26.78 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Piekos Brian — Chief Financial Officer | Option exercise (M): 5,000 · Sale (S): 1,489 @ $26.78 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Option exercise (M): 3,750 · Sale (S): 2,358 @ $26.78 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 23,250 · Sale (S): 10,926 @ $26.78 · Option exercise (M): 23,250 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 2,419 · Sale (S): 1,032 @ $26.76 · Option exercise (M): 2,419 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Option exercise (M): 1,774 · Sale (S): 1,108 @ $26.76 · Option exercise (M): 1,774 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 2,419 · Sale (S): 1,129 @ $26.76 · Option exercise (M): 2,419 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 7,120 · Sale (S): 3,322 @ $26.71 · Option exercise (M): 7,120 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 6,250 · Sale (S): 2,686 @ $20.22 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Sweeny Nicole — Chief Commercial Officer | Option exercise (M): 6,250 · Sale (S): 1,862 @ $20.22 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Piekos Brian — Chief Financial Officer | Option exercise (M): 6,250 · Sale (S): 1,862 @ $20.22 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 20,312 · Sale (S): 9,550 @ $20.22 · Option exercise (M): 20,312 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management III, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Sale (S): 174,485 @ $16.95 · Sale (S): 160 @ $17.53 · Sale (S): 21,386 @ $17.76 · Sale (S): 15,417 @ $18.82 · Sale (S): 3,183 @ $19.12 | EDGAR |
| 2026-03-10 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 15,625 · Sale (S): 6,693 @ $16.08 · Option exercise (M): 15,625 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 6,250 · Option exercise (M): 5,000 · Sale (S): 5,354 @ $15.57 · Option exercise (M): 6,250 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Sweeny Nicole — Chief Commercial Officer | Option exercise (M): 6,250 · Option exercise (M): 5,000 · Sale (S): 3,975 @ $15.57 · Option exercise (M): 6,250 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Piekos Brian — Chief Financial Officer | Option exercise (M): 5,000 · Sale (S): 1,767 @ $15.57 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Option exercise (M): 3,750 · Option exercise (M): 3,125 · Sale (S): 4,347 @ $15.57 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 23,250 · Sale (S): 10,034 @ $15.57 · Option exercise (M): 23,250 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 2,419 · Sale (S): 1,163 @ $15 · Option exercise (M): 2,419 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Yea Christopher — CHIEF DEVELOPMENT OFFICER | Option exercise (M): 1,774 · Sale (S): 1,109 @ $15 · Option exercise (M): 1,774 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 2,419 · Sale (S): 1,038 @ $15 · Option exercise (M): 2,419 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 7,120 · Sale (S): 3,354 @ $15.70 · Option exercise (M): 7,120 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Arif Bilal — Chief Operations Officer | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Sweeny Nicole — Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Piekos Brian — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Palleiko Benjamin L — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 15,625 · Sale (S): 7,294 @ $16.51 · Option exercise (M): 15,625 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Sweeny Nicole — Chief Commercial Officer | Option exercise (M): 6,250 · Option exercise (M): 5,000 · Sale (S): 3,813 @ $13.45 · Option exercise (M): 6,250 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Audhya Paul K. — CHIEF MEDICAL OFFICER | Option exercise (M): 6,250 · Option exercise (M): 5,000 · Sale (S): 5,296 @ $13.45 · Option exercise (M): 6,250 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Piekos Brian — Chief Financial Officer | Option exercise (M): 15,000 · Sale (S): 4,471 @ $13.45 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — KalVista Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-06-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-21 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KALV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →